Close Menu

NEW YORK (GenomeWeb) – Danaher today reported a 6 percent year-over-year increase in sales for the second quarter, and said that it has shut down its Veris molecular diagnostics product line as a result of its acquisition of Cepheid in late 2016.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.